177 results about "Hepatic Diseases" patented technology

The invention discloses a polypeptide or a pharmaceutically acceptable salt thereof. The polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or an amino acid sequence in a conservative modification form thereof. The polypeptide or the pharmaceutically acceptable salt thereof disclosed by the invention can be combined with GLP1R and is used for effectively activating the GLP1R. The GLP1R activating polypeptide is obtained through precise calculation and deep learning model optimization, has a short sequence, has unique amino acid arrangement compared with a traditional GLP-1 analogue, can effectively activate a GLP1R receptor, can also be used for treating or preventing metabolic disorder related diseases, and has a good application prospect. For example, obesity, diabetes, dyslipidemia related diseases, fatty liver diseases, metabolic syndromes, non-alcoholic fatty liver diseases and the like.

An application method of a modified peptide derived from Urechis unicinctus is to prepare a drug for treating alcoholic liver disease. The modified peptide derived from Urechis unicinctus is one or more selected from F2-1: IHVKF (SEQ ID NO: 1), F2-2: VHFKI (SEQ ID NO: 2), F4-1: GAWKP (SEQ ID NO: 3), F4-2: AGWKP (SEQ ID NO: 4), F5-1: GTLKP (SEQ ID NO: 5), F5-2: GTPKL (SEQ ID NO: 6), F7-1: IIVRM (SEQ ID NO: 7), and F7-2: IRMVI (SEQ ID NO: 8). The modified peptide derived from Urechis unicinctus can enhance the degradation of alcohol and boost the survival rate of cells with alcoholic liver disease, and also alleviate lipid metabolism and inflammation in mice, protecting liver from alcoholic liver disease. When applied in drug development for treating alcoholic liver disease, the application method offers low-risk, low-cost, and is simple to operate therapeutic options.

The invention discloses a multi-classification auxiliary prediction method and system for metabolism-related fatty liver diseases, electronic equipment and a storage medium, belongs to the field of medical data processing, and is used for solving the problem that a traditional MAFLD binary prediction model cannot fully reflect continuous pedigree of disease severity. The method comprises the following steps: acquiring clinical data related to classification prediction of metabolism-related fatty liver diseases; performing label coding, missing value filling and feature screening on the clinical data; and inputting the screened features into a TabNet classification model optimized by a particle swarm algorithm, and outputting a risk classification result of the metabolism-related fatty liver disease. According to the method, the severity of the fatty liver can be more accurately evaluated, the liver health condition of a patient is comprehensively reflected, and more accurate treatment guidance is provided for clinical diagnosis.

The invention relates to the technical field of liver disease prediction, in particular to a metabolism-related fatty liver disease intelligent prediction method and system and a storage medium. The method comprises the following steps: collecting multi-source data, respectively obtaining basic demographic information, laboratory indexes and prediction indexes, and extracting quantitative and qualitative tongue picture parameters; performing variable screening on the tongue picture parameters and the clinical indexes, and determining key prediction variables; obtaining a key variable value according to the key prediction variable, obtaining a prediction result of the occurrence risk of the metabolism-related fatty liver disease, and outputting the prediction result; the system comprises a multi-source data acquisition module, a variable screening module and a prediction result acquisition module. By means of the mode, the intelligent tongue picture parameters and the clinical indexes are fused, and the effect of early prediction of the metabolism-related fatty liver diseases is achieved.

The invention discloses application of a lucid ganoderma extract combined with clostridium butyricum in preparation of fat-reducing food or medicine. The invention finds that the ganoderma lucidum extract is combined with clostridium butyricum for use, so that the weight gain of a mouse induced by high-fat diet can be obviously slowed down, the epididymal fat weight of the high-fat mouse is reduced, and the lipid accumulation in the liver and serum of the mouse is reduced; according to the present invention, with the application of the polypeptide, the fat cell size is reduced, the expression of the key gene mRNA related to lipid metabolism and synthesis in the mouse liver is reduced, the intestinal flora of the mouse is regulated, the obesity can be well improved, and the important application prospect in the preparation of the drugs or food for treating diabetes, reducing blood fat, obesity and non-alcoholic fatty liver disease is provided.

The invention belongs to the technical field of biological medicines, and particularly relates to a traditional Chinese medicine composition for treating metabolism-related fatty liver diseases and a preparation method thereof. The technical problem to be solved by the invention is to provide a new choice for treating metabolism-related fatty liver diseases. According to the technical scheme, the traditional Chinese medicine composition for treating the metabolism-related fatty liver disease is prepared from the following components: radix paeoniae rubra, cyrtomium fortunei, curcuma zedoary, sculellaria barbata, herba epimedii, fingered citron, semen cassiae and herba artemisiae scopariae. The invention is mainly used for providing a new choice for treating the metabolism-related fatty liver disease, and has a wide application prospect.

The invention belongs to the technical field of traditional Chinese medicine research, and particularly relates to ganoderma lucidum polysaccharide and an extraction method and application thereof. The structural formula of the ganoderan is shown as a formula I in the specification. The ganoderan extracted by the invention can repair intestinal barriers by promoting the growth of beneficial intestinal bacteria, alleviate liver inflammation by targeting LPS / TLR4 / NF-kappa B / MAPK signal pathways, and reduce fat accumulation, thereby effectively alleviating the non-alcoholic fatty liver disease; and # imgabs0 #.

The invention belongs to the technical field of animal model construction, and particularly relates to a non-alcoholic fatty liver disease mouse model based on humanized PNPLA3 I148M transgene as well as a construction method and application thereof, the construction method comprises the following steps: step i: designing CDS of a human gene and a key 3 'UTR element for patent medicine of a small nucleic acid drug in gene plasmid DNA of the constructed model; step ii, using Luc2 or iRFP to report gene expression in the gene plasmid DNA for constructing the model; and (iii) a disease model of the fatty liver disease induced by combining plasmid DNA transient transfer with high-fat diet. The mouse model constructed by the invention has the advantages that a specific exogenous gene expression signal of the liver is detected in real time through small animal living imaging, a human PNPLA3 protein is detected and overexpressed through serum ELISA, PNPLA3 I148M mRNA is detected and overexpressed through liver RT-qPCR, the phenotype of the non-alcoholic fatty liver disease of the liver is determined through 15-week-old pathology, and the whole process of modeling for 8 weeks does not need to be operated in a biosafety secondary laboratory.

The invention discloses a cadinane type sesquiterpene as well as a preparation method and application thereof. The cadinane type sesquiterpene is separated from cinnamon bark, and has at least one of structural formulas shown as a formula (I), a formula (II), a formula (III) and a formula (IV). Liver protection activity evaluation is carried out by applying an alcohol-induced hepatocyte injury model, and it is found that the cadinane type sesquiterpene can effectively relieve alcohol-induced AML-12 hepatocyte injury; the dumarane sesquiterpenes can inhibit the alcoholic liver disease and relieve fat accumulation, so that the dumarane sesquiterpenes have the anti-alcoholic liver disease activity, can be applied to preparation of the anti-alcoholic liver disease drugs, and have good research and development prospects; belongs to the field of natural medicinal chemistry.

The invention provides a mulberry phellinus linteus strain SH08, mulberry phellinus linteus polysaccharide as well as a preparation method and application of the mulberry phellinus linteus polysaccharide, and belongs to the technical field of biological medicines and functional foods. The mulberry phellinus igniarius strain SH08 provided by the invention is preserved in the China Center for Type Culture Collection on October 11, 2025, the preservation address is No. 299, eight road, Wuchang District, Wuhan City, Hubei Province, the strain preservation number is CCTCC NO: M20252203, and the mulberry phellinus igniarius strain SH08 is named as SanghuangAKSQSH01. The invention also provides a method for preparing high-purity mulberry phellinus linteus polysaccharide (SHP-PS) from sporocarp of the strain, and structural characterization of the polysaccharide. Experiments prove that the SHP-PS can effectively improve non-alcoholic fatty liver disease (NAFLD) induced by high fat diet, and the mechanism of the SHP-PS is closely related to blood fat regulation, liver injury and inflammation reduction, intestinal barrier repair, intestinal flora structure regulation and short-chain fatty acid generation promotion. The invention provides high-quality raw materials and a clear technical scheme for developing novel medicines or functional foods for preventing and treating NAFLD, and has important application value.

The application discloses a high-activity UGT1A1 enzyme based on tree shrew and a feed composition for enhancing alcohol metabolism. The catalytic efficiency of the recombinant tree shrew UGT1A1 enzyme on ethanol is significantly higher than that of human isozyme. The core of the application is to provide a complex feed system containing the enzyme, which solves the key bottleneck of poor stability and low delivery efficiency of exogenous enzymes in application through the synergistic effect of enzyme stabilizers, cell penetration enhancers, enteric coatings and coenzyme supply agents. Animal experiments show that the composition can safely and effectively accelerate in vivo alcohol elimination and reduce blood ethanol concentration, and can be used for developing alcoholism products, acute alcoholism treatment drugs and alcoholic liver disease prevention preparations.

The invention discloses a composition for preventing and / or treating alcoholic liver diseases, a product and application thereof. The present invention relates to a composition comprising: breast milk oligosaccharides and vitamins; the breast milk oligosaccharide comprises fucosyllactose and sialic acid lactose; the composition can provide nutritional support for patients with alcoholic liver diseases, repair intestinal mucosal barrier, reduce endotoxin entering blood, improve abundance of beneficial bacteria in intestinal tracts and reduce inflammatory response, so as to achieve the purpose of preventing and / or treating alcoholic liver diseases induced by alcohol.

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

The invention relates to the technical field of biological medicines, and discloses application of INHBC as a target spot in prevention and / or treatment of metabolic diseases. Specifically, the invention relates to application of substances for promoting INHBC gene expression or improving protein activity in preparation of products for preventing and / or treating metabolic diseases, and the metabolic diseases comprise diseases caused by energy metabolism disorder, such as obesity, diabetes, fatty liver disease, hyperlipidemia and the like. According to the application disclosed by the invention, liver specific overexpression or INHBC knock-in can improve mouse liver fatty degeneration and abnormal glucose metabolism induced by high fat diet, and in addition, the heat production activity of mouse adipose tissues can be enhanced, so that obesity induced by high fat diet is inhibited; the compound has an important application value in preventing and / or treating metabolic diseases such as obesity, type 2 diabetes and fatty liver diseases.

The present invention relates to the medical use of specific long-acting glycemic analogs having dual GLP-1 / glycemic receptor agonist activity for the prevention and / or treatment of metabolic liver diseases, in particular non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NAFLD-related hepatic fibrosis and / or cirrhosis.

The invention discloses an extraction process method of a functional gastrodia elata wine partner and application of the functional gastrodia elata wine partner in alcoholic liver injury, and belongs to the technical field of biology. In order to improve the diversity of edible gastrodia elata products and solve the problems of long consumed time, low solubility, low leaching rate of active substances and the like of traditional gastrodia elata wine, the invention provides a new concept of gastrodia elata wine partners. Artificial intelligence and a response surface are combined, and optimal extraction process parameters are optimized and obtained as follows: the volume fraction of ethanol is 50%, the material-liquid ratio is 1: 20 g / mL, the ultrasonic time is 1.55 h, the ultrasonic temperature is 58 DEG C, and the ultrasonic power is 490 W; network pharmacology and molecular docking reveal that the gastrodia elata wine partner has a potential protection effect on alcoholic liver diseases; cell tests show that the gastrodia elata wine partner has a remarkable protection effect on HegG2 cells, and animal experiments further reveal that the gastrodia elata wine partner can effectively reduce the ethanol content of rat eye socket blood and has potential advantages in the aspects of reducing free radical damage and improving the oxidative stress state. The convenient edible product and the matching mode are expected to become beneficial supplement of the modern drinking culture, and the liver health is protected while people enjoy delicious wine.

The research finds that the SUMOylation level of the liver in a clinical specimen and an animal model of the metabolic dysfunction fatty liver disease is obviously reduced. UBC9 is used as the only key E2 ligase for SUMOylation to regulate and control the SUMOylation level. The invention discloses application of a UBC9 gene overexpression preparation in drugs for treating or preventing metabolic dysfunction fatty liver diseases. Through overexpression of liver specificity UBC9 mediated by an AAV adeno-associated virus vector or overexpression of UBC9 in HepG2 cells by a lentiviral vector, lipid deposition of a C57 mouse liver induced by high fat diet and a cell model treated by palmitate can be remarkably improved, and reduction of the SUMOylation level of the mouse liver and the human HepG2 cells under the high fat background can be reversed. Therefore, the UBC9 gene overexpression preparation can be used for developing drugs for treating metabolic dysfunction fatty liver diseases.

This invention relates to a composition for improving alcoholic liver damage, belonging to the field of health product technology. This application provides the use of rhodioloside and lactose-N-trisaccharide in the prevention and / or inhibition of alcoholic liver disease. This application also provides a composition of human lactose oligosaccharides and rhodioloside. The compositions described in this application can prevent the occurrence of alcoholic liver disease or inhibit its further deterioration. This application provides a green, safe, and healthy composition, offering an ideal composition for protecting human health.

This invention discloses the application of American ginseng glycoprotein extract in the preparation of drugs for treating alcoholic liver disease, belonging to the field of biomedical technology. This invention verifies that TD can significantly reduce serum ALT, AST, and TG levels in ALD mice, effectively reducing liver damage and lipid accumulation; inhibit NLRP3 protein expression and its downstream targets, effectively alleviating liver inflammation and pyroptosis; and improve intestinal flora imbalance in ALD mice. American ginseng glycoprotein extract has multi-target protective effects against alcoholic liver disease, reducing alcohol-induced liver tissue inflammation and oxidative stress damage. It has a mild composition and high safety profile, and can synergistically exert effects in liver protection, anti-inflammation, and antioxidation, making it suitable for adjunctive intervention and long-term management of alcoholic liver disease, providing a natural, mild, and effective protective pathway for alcoholic liver damage.

The invention belongs to the field of medicine, and particularly relates to application of apium graveolens extract to preparation of medicine for treating fatty liver diseases related to metabolic dysfunction. The celery and sophora flower extract is an alcohol extract of celery seeds and sophora flower buds in a weight ratio of (1: 1)-(4: 1), preferably (3: 1)-(4: 1), and further preferably (3: 1). The invention provides a new choice for clinical medication for treating fatty liver diseases related to metabolic dysfunction, and has great clinical value and social significance.

The invention belongs to the technical field of biology, and discloses application of DVM nanoparticles in preparation of products for treating and / or preventing alcoholic liver diseases, the DVM nanoparticles contain gallic acid derivatives VM and dihydromyricetin; the mass ratio of the gallic acid derivative VM to the dihydromyricetin is 1: 3; in alcohol-induced HepG2 cells, the DVM nanoparticles can better reduce apoptosis of hepatocytes and generation of ROS, improve ADH activity, reduce AST and ALT activities in the cells and improve the hangover alleviating ability in mice, and have a more excellent liver protection effect compared with gallic acid and a positive drug silibinin.

The invention discloses application of a ginseng-keto capsule in treatment of non-alcoholic fatty liver disease, and belongs to the technical field of biological medicine. The tanshinone capsule is used for treating the non-alcoholic fatty liver disease. According to the method, firstly, systematic chemical component analysis is performed on the TSN through an LC-MS / MS technology, and the result shows that the TSN has typical characteristics of multiple components, multiple categories and multiple targets, so that a material basis is laid for playing a multi-link comprehensive intervention role in NAFLD; the essential difference is formed from the existing mechanism research carried out only aiming at a single component (such as dihydrotanshinone I and rosmarinic acid).

This invention belongs to the technical field of natural product active ingredients, specifically relating to a glycopeptide LBGP-I-b derived from wolfberry and its uses. The glycopeptide LBGP-I-b has an average molecular weight of 700–1000 Da, a polypeptide content of 70%–80%, and a polysaccharide content of 10%–20%. The sugar chains are composed of glucose residues, and the sugar chains are linked to the peptide chains via O-glycopeptide bonds. The glycopeptide has functions such as regulating lipid metabolism, lowering blood lipid levels, and improving liver function. The glycopeptide of this invention has a clear source and stable properties, and has good application prospects in the prevention and treatment of metabolic diseases such as metabolic-related fatty liver disease.

The invention provides application of lactobacillus brevicornu and a fermentation composition thereof in hangover alleviating and liver protection, and relates to the technical field of biological fermentation, the lactobacillus brevicornu is lactobacillus brevicornu, the strain number of the lactobacillus brevicornu is KMHD10-222, and the registration number of the lactobacillus brevicornu in the China General Microbiological Culture Collection Center is CGMCC No. 32358. Traditional Chinese medicine substrates can be fermented, and the hangover-alleviating and liver-protecting effects of fermentation products are enhanced. The content of rare ginsenoside, total polysaccharide, total flavone, total phenol, puerarin, daidzein and dihydromyricetin of the lactobacillus brevis KMHD10-222 fermentation substrate extracting solution is increased, the effects of promoting ethanol metabolism and improving the alcoholic liver disease can be improved, and the effects of dispelling the effects of alcohol and protecting the liver are achieved.

The invention provides a small molecule compound A1 which has a good treatment effect on metabolism-related fatty liver diseases. The structural formula of the hydroxyl pyrene compound A1 is shown in the specification. The invention further provides a medicine for preventing and / or treating the metabolism-related fatty liver disease and application of the compound in vivo and in vitro. In-vivo and in-vitro experiments prove that A1 has a remarkable treatment effect on metabolism-related fatty liver diseases. Liver fatty degeneration can be improved, and a definite reversing effect on hepatic fibrosis is achieved. Meanwhile, the compound A1 has better safety, and provides an effective means for preventing and treating the metabolism-related fatty liver diseases.

The present invention relates to a HIF2α gene mutant, a vector, and their use in constructing a NAFLD mouse model. Genetically modified mice constructed using this mutant can be stably propagated, facilitating practical studies of the pathogenic mechanisms of the HIF2α gene in mice with non-alcoholic fatty liver disease (NAFLD). Given the limited availability of human NAFLD livers and the constraints of medical ethics, the mouse model provided in this application will become an important tool in NAFLD research, providing a stable, heritable research model for studies of pathogenic mechanisms, treatments, and drug screening.

This invention provides an application of tartary buckwheat antioxidant peptide as a PPARα agonist. The tartary buckwheat antioxidant peptide (SEQ ID NO:1) is used to prepare a PPARα agonist, and this tartary buckwheat antioxidant peptide is used to prepare a drug for improving metabolic dysfunction-related fatty liver disease (MASLD). The tartary buckwheat antioxidant peptide of this invention provides a new drug candidate for improving MASLD and has broad clinical application prospects.

The invention relates to application of combination of hyperoside and salvianolic acid B to preparation of a medicine for treating NAFLD, and belongs to the technical field of biological medicine. The hyperoside and the salvianolic acid B have a synergistic effect in preparation of the medicine for treating the non-alcoholic fatty liver disease when used in combination according to the required treatment amount, the curative effect can be enhanced and the side effect can be reduced through combined use of the two medicines, the effect is better than that of independent medication, a new thought is provided for treating the non-alcoholic fatty liver disease, and the application prospect is wide. The method has important significance and wide application prospects.

The invention discloses a metabolism-related fatty liver disease single cell data set visualization method and system, and belongs to the technical field of bioinformatics, and the method comprises the following steps: S1, establishing a relational data table including a single cell data set and cell information of single cell data; and S2, visually displaying single cell data analysis results according to the relational data table, wherein the single cell data analysis results comprise a clustering diagram, an expression spectrum, a hypervariant gene point diagram, a volcano diagram, a pathway enrichment diagram and a cell interaction point diagram. Compared with an existing scheme, the method has higher interactivity and supports various interactive operations such as zooming, clicking and suspension. All the graphs call cloud data in real time and render the cloud data in real time based on a user request, and dynamic updating of visual content is ensured. Compared with the prior art, in the prior art, an analysis result is generally made into a static bitmap and then imported into a database, interactive operation cannot be carried out, an image needs to be regenerated once data is updated, and the requirements for real-time performance and flexibility are difficult to meet.

The present invention relates to the use of the Lactobacillus helveticus BGRA43 strain for the prevention and / or treatment of liver diseases and / or liver disorders, preferably metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (N AFLD), and / or for the reduction of liver steatosis. The formulation, preferably for peroral administration, comprising the L. helveticus BGRA43 strain. The formulation comprising the L helveticus BGRA43 strain, which is preferably a probiotic food product intended for human consumption. Lyophilizate of the L helveticus BGRA43 strain, comprising the L. helveticus BGRA43 strain at a concentration from 108 to 1013 CFU / g.